NCT06383884View on ClinicalTrials.gov

Patritumab Deruxtecan in Patients with Solid Tumor Harboring an NRG1 Fusion

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
Solid Tumor, Adult
Interventions
DRUG

Patritumab Deruxtecan

Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day cycle as a fixed dose regimen of 5.6 mg/kg Q3W.

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER